Sumary of Greater lumbar spine BMD gains with romosozumab for postmenopausal women:
- July 22, 2021 3 min read Source/Disclosures Published by: Disclosures: Brown reports he has received research support from Mereo BioPharma, Radius Health and Servier, has served as a consultant for Amgen and Servier, and has served on speakers bureaus for Amgen.
- Back to Healio Postmenopausal women with osteoporosis receiving romosozumab for 12 months had larger improvements in bone mineral density and bone strength at the lumbar spine compared with those receiving alendronate alone, according to study data.
- Data from the ARCH trial showed 1 year of romosozumab-aqqg (Evenity, Amgen) followed by a year of alendronate was associated with larger BMD gains compared with 2 years of alendronate treatment alone.
- In a substudy of ARCH, romosozumab was also associated with greater gains in integral, cortical and trabecular volumetric BMD and bone mineral content compared with alendronate alone.
- alendronate in the ARCH trial and provide insights into structural determinants of this differential treatment effect,” Jacques P.
- “The key takeaway from our analysis of data from the ARCH trial is that romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women, and that this improvement is due to the differential treatment effects of romosozumab vs.
- alendronate on the cortical and trabecular bone compartments of the lumbar spine.
- ” ARCH is a phase 3, multicenter, randomized, double-blind trial in which postmenopausal women with osteoporosis and a prior fragility fracture were randomly assigned to 210 mg romosozumab monthly or 70 mg oral alendronate weekly for 12 months.